

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
05 January 2023 (05.01.2023)



(10) International Publication Number
WO 2023/278683 A1

(51) International Patent Classification:

A61K 38/26 (2006.01) A61K 38/27 (2006.01)
A61K 38/00 (2006.01) C07K 1/00 (2006.01)
A61K 38/16 (2006.01)

NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU,
RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM,
TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM,
ZW.

(21) International Application Number:

PCT/US2022/035699

(22) International Filing Date:

30 June 2022 (30.06.2022)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/216,688 30 June 2021 (30.06.2021) US

(71) Applicant: ALLYSTA PHARMACEUTICALS, INC.

[US/US]; 12819 SE 38th Street, Box #148, Bellevue, Wash-
ington 98006 (US).

(72) Inventors: HSU, Henry; Allysta Pharmaceuticals, Inc.,

12819 SE 38th Street, Box #148, Bellevue, Washington
98006 (US). OTVOS, Laszlo; 801 Mockingbird Lane,
Audubon, Pennsylvania 19403 (US).

(74) Agent: SUN-HOFFMAN, Lin; P.O. Box 52048, Palo Alto,

California 94303 (US).

(81) Designated States (unless otherwise indicated, for every

kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH,
KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA,
MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI,

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,

GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the
claims and to be republished in the event of receipt of
amendments (Rule 48.2(h))
- with sequence listing part of description (Rule 5.2(a))

(54) Title: MONOMERIC FUSION PEPTIDES AND METHOD OF USE THEREOF




FIG. 1A

(57) Abstract: A fusion peptide comprising a GLP1 variant, and at least one adiponectin agonist peptide which is chemically attached to the GLP1 variant via a spacer. The GLP1 variant portion can include one or more substitutions relative to the native GLP1. The adiponectin agonist peptide can be attached to the GLP1 variant at different attachment sites. A method of treating a metabolic disorder or condition using the fusion peptide is also provided.



WO 2023/278683 A1